> the national pharmaceutical group, a pharmaceutical “national team” with more than 1,600 member enterprises, is ostensibly a conglomerate with a national basic drug security mandate, but its “new quality productivity” at the beginning of the “fifty-fifty five” exercise, the core is a clear business logic for building the city river through systematic technological innovation, and thereby realizing it in aggregate and global markets. In action, it answered a central proposition: in the high-barrier industry of medicine, where does chinese business come from and whether it will be sustainable? # technology breakthroughs, which point directly to cost and innovation in the “seven inches” of the supply chain’s “national pharmaceutical group”, are not without purpose, and their technological implications are precisely aimed at two commercial destinations:** reducing absolute costs** and** safeguarding supply chain security**. In the case of high blood pressure generic nitro tablets, the core technology, “infiltration pump control”, has long been monopolized abroad. The team of national medicine modern uniteds, which has been running through software and hardware on eight occasions**, has managed to tackle the problem of precision laser holes in high-speed rotations and achieve nationalization. The commercial value of this breakthrough is immediately visible: the self-developed laser piercing equipment has resulted in the production of ** waste tablets as low as 0. 1 per cent**, while the team successfully replaced “infiltration propellants” as a key material entirely dependent on imports with national production aids. Ultimately, the cost of domestically produced medicines has been reduced to about one third of the cost of imported medicines, becoming the core weapon of their participation in the national collection and rapid occupation of markets. The same logic is reflected in the biopharmaceutical field. The “injecting recombinant cortex” for rare epilepsy, using animal extraction abroad, cost more than $ **. 2 million per treatment.** the national institute of medicine and medicine has increased the purity of drugs to more than **99 per cent** and reduced costs to “under 1/10 of imported drugs” through genetic re-engineering techniques. This has not only addressed the clinical dilemma of “no drugs”, but has also created a large potential market for commerce, ranging from “no drugs” to “accessible”. #ai and smart manufacturing: from the “blackhouse key” to the “scientific efficiency” of r & d and production, it is directly related to the profitability and responsiveness of enterprises. The national drug group is incorporating ai and smart manufacturing depths into these two links to change its cost structure. At the research and development end, traditional drug screening has been described by researchers as “the search for keys in a dark room, which may not be found until dawn”. The ai prediction platform set up by the national medicines and china biologicals in shanghai enables several days of protein structure prediction and screening for traditional methods to be completed within ** milliseconds**, fast-tracking targets from millions of tumor genetic mutations. The ai-driven, robot-implemented “dry-wet closed-ring” development platform at the national college of pharmaceuticals and medicines' center for systems biosynthetic research, which allows the screening of tens of thousands to millions of samples per day, significantly shortens the early research and development cycle. (blockview://markdown-image-tos-cn-i-tt/b9b352d4d4d424ef8ac06e5d2f82394d2) at the production end, intellectualization means lower loss and higher quality stability. The above-mentioned 0. 1 per cent waste rate** benefits from the ai visual detection system. In the bioworks workshop,** the national production rate of critical equipment for single resistance lines is over 90 per cent,** and real-time monitoring and early warning of more than 200 process parameters ensures inter- batch quality stability. (blockview://markdown-image-tos-cn-i-t/4f4bcc9919c4f699366e3ce16a2c1a4) the shanghai biological products institute's influenza vaccine production line, which is automated per batch ** 250,000 chicken embryos**, achieved the elastic increase in production reserves. # harvest structures: the cost advantages of technological breakthroughs in the harvesting of ballasts and outages will ultimately have to be realized on the market. The income composition of the national pharmaceutical group clearly reflects its commercial strategy:** deep binding of the national csds fundamentals while taking advantage of quality to open up incremental space**. - **strategic basics**: modernity of the national medicines of the chemical pharmaceutical platforms under the flag is the implementer of this strategy. By the end of 2025, companies had accumulated **65 varieties** selected in national drug collections, which in 2025 contributed ** 2,472 million yuan** sales revenue, or 55 per cent of their agent revenues**. Through an integrated strategy of “pesticide + formulations”, modern national medicines have created a cost advantage in the collection of competitive prices, while at the same time targeting large market shares. Its national and provincial collection of covered medicines has exceeded **500 ** and has secured ballast stones for civilian life medicine. - ** seaside growth line**: the dual advantage of cost and quality makes national pharmaceutical products internationally competitive. Modern core raw drugs and preparations for national medicines have been certified by authorities such as the united states fda, the european union's ceo, and exports cover more than 70 countries and territories,** and have been successful in retrogressing supply chains of multinational companies. This is not only to earn foreign exchange, but also to reshape the brand image of “china makes” in the field of medicine with high-quality standards, opening up long-term growth space. # platform support: the sustained ability to generate “infrastructure” for sustainable innovation depends on sustainable innovation. The national drug corporation has built a vast and innovative infrastructure system to ensure the sustainable release of its technological dividends. The system includes ** two national priority laboratories, 44 national strategic science, technology and innovation platforms** and specialized r & d services such as the general college of health and industry (cumulative certification of 279 new medicines) and winnox (the country's first firm, cro, listed). (blockview://markdown-image-tos-cn-i-tt/d300fea606060f4d96bf2d249f572b8948) their role is similar to that of the pharmaceutical industry's “national laboratory + incubator”, covering the full chain from target detection, safety evaluation to mid-test transformation. Of particular note is the experimental evidence platform, which addresses the difficulty of “thousands of times magnifying” laboratory results to industrialization and has successfully helped to complete the preparation of clinical samples**. This means that national pharmaceutical groups not only have the capacity to carry out front-line r&d, but also have more access to efficient and low-cost r&d to market products, creating a closed circle from “money for r&d” to “money for development”. ** clear conclusion**: the new qualitative productivity of national pharmaceutical groups is essentially a profound commercial change driven by national demand and targeted at marketization. It has built a deep **-cost moat** in the area of high-end agents and biopharmaceuticals by attacking key technologies and equipment; thus winning the fundamentals in the collective market and achieving a breakthrough in brand names and profits on the international market; its vast system of creative platforms has provided a sustainable supply of “ammunition”. Its path proves that the largest commercial opportunities in the chinese pharmaceutical market are often hidden in the re-engineering of costs and supply chain security after the capture of the “crawling” technology。
